BioSpace News Archive

The New School Food Markets Program will be introduced in the Jennings, Mo. and Cahokia, Ill. School Districts

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Mr. Jonathan Wener, Chairman of the Board of Canderel Management Inc. and founder of the Défi Canderel Challenge, remitted two cheques totalling over 2.4 million dollars to the representatives of two Montreal cancer research centres: the Institut du cancer de Montréal, affiliated with the Université de Montréal, and the Rosalind and Morris Goodman Cancer Centre at McGill University.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, recently presented its current plans for an Adaptively Designed Phase 3 clinical trial (NASH-RX) of its lead compound, belapectin (GR-MD-02), in the treatment of patients with nonalcoholic steatohepatitis (NASH) cirrhosis without esophageal varices.

Combination of BL-8040, KEYTRUDA® and chemotherapy showed high level of disease control, including 4 partial responders and 8 patients with stable disease out of 15 evaluable patients

ACTO achieved 158% year to date revenue growth and has digitally transformed over 50 life sciences companies, including global pharma, medical device, and dental companies.

The majority of patients received riluzole alone, 4.2% were receiving edaravone alone, and 20.6% were receiving both.

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the 38th Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2020, in San Francisco, California

Technavio has announced its latest market research report titled global kidney stones management devices market 2019-2023

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference in New York City.